Showing results (31-40 of 62) with videos related to
Sort By:
Pageof 7
Translational Cancer Research|February 4, 2022
The clinical prognostic factors of patients with stage IB lung adenocarcinomaQihai Sui, Jiaqi Liang, Zhengyang Hu, et al.Translational Oncology|December 18, 2025
The stem cell atlas of lung adenocarcinoma: A stemness blueprint for prognosis and immunotherapy successJiacheng Yin, Xing Jin, Zhengyang Hu, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 24, 2024
MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinomaJiaqi Liang, Guoshu Bi, Yiwei Huang, et al.Cancer Medicine|October 7, 2021
Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomasXing Jin, Yuansheng Zheng, Zhencong Chen, et al.Thoracic Cancer|October 1, 2021
Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinomaHuan Zhang, Guangyao Shan, Benjie Cai, et al.Heliyon|September 12, 2024
Dissection of the cell communication interactions in lung adenocarcinoma identified a prognostic model with immunotherapy efficacy assessment and a potential therapeutic candidate gene ITGB1Xing Jin, Zhengyang Hu, Jiacheng Yin, et al.Immunogenetics|November 14, 2020
Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinomaMengnan Zhao, Ming Li, Zhencong Chen, et al.Heliyon|December 12, 2022
Identification and validation of the mitochondrial function related hub genes by unsupervised machine learning and multi-omics analyses in lung adenocarcinomaXing Jin, Huan Zhang, Qihai Sui, et al.Journal of Translational Medicine|April 12, 2022
Cisplatin resistance-related multi-omics differences and the establishment of machine learning modelsQihai Sui, Zhencong Chen, Zhengyang Hu, et al.Cell Reports|February 9, 2024
Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinomaJiaqi Liang, Guoshu Bi, Qihai Sui, et al.Pageof 7